Oncolytics Biotech Inc. Announces Reovirus Clearance Patent
"The results of this study demonstrated that the reovirus may have a role to play in purging contaminating cancer cells from stem cell preparations used for transplants," said Dr. Matt Coffey, Chief Scientific Officer for Oncolytics. Hematological stem cell rescue following high-dose chemotherapy is extensively used clinically for both solid tumours and tumours of the blood. Globally, the number of autologous blood and bone marrow transplants surpasses the number of donor-derived transplants. It has been estimated that as many as 30 per cent of these autologous stem cells transplants are contaminated by cancer cells, and may contribute to clinical relapse of the cancer.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.